Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБУ Московский научно-исследовательский институт психиатрии Минздрава России; 2ФГБОУ ВПО Московский педагогический государственный университет
Список исп. литературыСкрыть список 1. Горобец Л.Н., Матросова М.И. Сравнительная динамика уровней пролактина и эндокринных показателей у больных с первым психотическим эпизодом и хронической шизофренией в процессе терапии оланзапином. Уральский журн. психиатрии, наркологии и психотерапии. Екатеринбург, 2013; 1 (3): 29–36. 2. Гурович И.Я., Шмуклер А.Б., Магомедова М.В. и др. Первый психотический эпизод: особенности терапии оланзапином. Соц. и клин. психиатрия. 2004; 14 (2): 62–7. 3. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция негативных и позитивных расстройств. М.: Новый цвет, 2001. 4. Основы нейроэндокринологии. Под ред. В.Г.Шаляпиной и П.Д.Шабанова. СПб.: ЭЛБИ-СПб., 2005; с. 472. 5. Bicikova M, Hampl R, Hill M et al. Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol Lett 2011; 32 (2): 141–7. 6. Brophy MH, Rush AJ, Crowley G. Cortisol, estradiol, and androgens in acutely ill paranoid schizophrenics. Biol Psychiat 1983; 18: 583–90. 7. Cohrs S, Röher C, Jordan W et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacol (Berl) 2006; 185 (1): 11–8. 8. di Michele F, Caltagirone C, Bonaviri G et al. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiat Res 2005; p. 267–73. 9. Erb JL, Kadane JB, Tourney G et al. Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements. J Clin Endocrinol Metab 1981; 52: 181–6. 10. Gallagher P, Watson S, Smith MS et al. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res 2007; 90: 258–65. 11. Jakovljevic M, Pivac N, Mihaljevic-Peles A et al. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog Neuropsychopharmacol Biol Psychiat 2007; 30; 31 (2): 399–402. 12. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Ann Rev Med 2001; 52: 503–17. 13. Marx CE, Stevens RD, Shampine LJ et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacol 2006; 31: 1249–63. 14. Mondelli V. The effect of stress and its biological mediators on the onset and clinical outcome of psychosis. Eur Arch Psychiat Clin Neuroscience 2013; 263: 7. 15. Nechmad A, Maayan R, Ramadan E et al. Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. Eur Neuropsychopharmacol 2003; 13 (1): 29–31. 16. Oades RD, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinol 1994; 19: 373–85. 17. Oertel GW, Benes P, Schirazi M et al. Interaction between dehydroepiandrosterone, cyclic adenosine-3’,5’-monophosphate and glucose-6-phosphatedehydrogenase in normal and diseased subjects. Experiential 1974; 30: 872–3. 18. Orentreich N, Brind JL, Rizer RL et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59 (3): 551–5. 19. Owen M, Wolkowitz HD, Antony J. Psychoneuroendocrinology: the scientific basis of clinical practice 2003; p. 588. 20. Owen RR Jr, Gutierrez-Esteinou R, Hsiao J et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiat 1993; 50 (8): 636–44. 21. Ritsner M, Gibel A, Ram E et al. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur Neuropsychopharmacol 2006; 16 (137): 146. 22. Ritsner M, Maayan R, Gibel A et al. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Eur Neuropsychopharmacol 2007; 17: 358–65. 23. Ryan MC, Flanagan S, Kinsella U et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74 (16): 1999–2008. 24. Strous RD, Maayan R, Lapidus R et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res 2004; 71 (2–3): 427–34. 25. Tanaka K, Morinobu S, Ichimura M et al. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiat 2008; 32 (6): 1527–32. 26. Tourney G, Erb JL. Temporal variations in androgens and stress hormones in control and schizophrenic subjects. Biol Psychiat 1979; 14: 395–404. 27. Venkatasubramanian G, Chittiprol S, Neelakantachar N et al. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res 2010; 119 (1–3): 131–7.